|CorMedix Inc. (CorMedix), incorporated in July 28, 2006, is a biopharmaceutical company that focuses on in-licensing, developing and commercializing therapeutic products for the treatment of cardiac and renal dysfunction, also know as Cardiorenal disease. The Company has licensed all of the products in its Cardiorenal pipeline. The Company has several product candidates in clinical development, including its product candidates, CRMX003 (CorMedix Neutrolin), a liquid designed to prevent central venous catheter infection and clotting initially in dialysis catheters, and CRMX001 (the Company’s formulation of the drug deferiprone), which targets the prevention of contrast-induced nephropathy in patients. The Company has two foundational platforms. Its first foundational platform focuses on utilizing liquid and gel formulations of Neutrolin (CRMX003 and CRMX004, respectively) to prevent the infection and clotting that can occur with the use of central venous catheters and peripherally inserted central catheters. These catheters are used for vascular access in hemodialysis, for cancer chemotherapy, long term antibiotic therapy, total parenteral nutrition and intensive care patients. CorMedix’s second foundational platform focuses on reducing excess free (labile) iron, which is toxic to cells and tissues, using CRMX001, its formulation of the drug deferiprone.